Gordon Chan

Summary

Affiliation: University Health Network
Country: Canada

Publications

  1. doi request reprint The tyrosine phosphatase Shp2 (PTPN11) in cancer
    Gordon Chan
    Ontario Cancer Institute, Toronto, ON, Canada
    Cancer Metastasis Rev 27:179-92. 2008
  2. pmc Essential role for Ptpn11 in survival of hematopoietic stem and progenitor cells
    Gordon Chan
    Cancer Biology Program, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
    Blood 117:4253-61. 2011
  3. pmc Erk1 and Erk2 are required for maintenance of hematopoietic stem cells and adult hematopoiesis
    Gordon Chan
    Campbell Family Cancer Research Institute, Ontario Cancer Institute, Toronto, ON, Canada
    Blood 121:3594-8. 2013
  4. pmc Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis
    Gordon Chan
    Department of Stem Cell and Developmental Biology, Ontario Cancer Institute, Toronto, ON, Canada
    Blood 113:4414-24. 2009
  5. ncbi request reprint Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations
    M Golam Mohi
    Cancer Biology Program, Department of Medicine, Beth Israel Deaconess Medical Center, 77 Avenue Louis Pasteur, NRB 1030, Boston, Massachusetts 02115, USA
    Cancer Cell 7:179-91. 2005
  6. pmc Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardial-mesenchymal transformation
    Toshiyuki Araki
    Division of Hematology Oncology and Cancer Biology Program, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 106:4736-41. 2009

Detail Information

Publications6

  1. doi request reprint The tyrosine phosphatase Shp2 (PTPN11) in cancer
    Gordon Chan
    Ontario Cancer Institute, Toronto, ON, Canada
    Cancer Metastasis Rev 27:179-92. 2008
    ..Elucidation of the events underlying Shp2-evoked transformation may provide new insights into oncogenic mechanisms and novel targets for anti-cancer therapy...
  2. pmc Essential role for Ptpn11 in survival of hematopoietic stem and progenitor cells
    Gordon Chan
    Cancer Biology Program, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
    Blood 117:4253-61. 2011
    ..Thus, Shp2 plays a critical role in controlling the survival and maintenance of HSCs and immature progenitors in vivo...
  3. pmc Erk1 and Erk2 are required for maintenance of hematopoietic stem cells and adult hematopoiesis
    Gordon Chan
    Campbell Family Cancer Research Institute, Ontario Cancer Institute, Toronto, ON, Canada
    Blood 121:3594-8. 2013
    ..Moreover, in cells transformed by the oncogenic KRas(G12D) allele, the presence of either Erk1 or Erk2 with intact kinase activity is sufficient to promote cytokine-independent proliferation...
  4. pmc Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis
    Gordon Chan
    Department of Stem Cell and Developmental Biology, Ontario Cancer Institute, Toronto, ON, Canada
    Blood 113:4414-24. 2009
    ..Our studies provide a mouse model for Ptpn11-evoked MPD and show that this disease results from cell-autonomous and distinct lineage-specific effects of mutant Ptpn11 on multiple stages of hematopoiesis...
  5. ncbi request reprint Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations
    M Golam Mohi
    Cancer Biology Program, Department of Medicine, Beth Israel Deaconess Medical Center, 77 Avenue Louis Pasteur, NRB 1030, Boston, Massachusetts 02115, USA
    Cancer Cell 7:179-91. 2005
    ..Shp2 mutants also cause myeloproliferation in Drosophila. Mek or Tor inhibitors potently inhibit transformation, suggesting new approaches to JMML therapy...
  6. pmc Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardial-mesenchymal transformation
    Toshiyuki Araki
    Division of Hematology Oncology and Cancer Biology Program, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 106:4736-41. 2009
    ..Our data provide a mechanistic underpinning for the cardiac defects in this disorder...